Time in target range (TTR) is parameter that measures how much time patients spend within a target blood pressure (BP range. TTR is considered as an effective measure of BP control and increasing TTR has been associated with reductions in CV risks, including stroke, heart attack, and death.

-

Three-year data from SPYRAL HTN-ON MED and GSR-DEFINE on TTR after renal denervation were recently presented at EuroPCR 2022.

The SPYRAL HTN-ON MED randomized patients with uncontrolled hypertension despite being on 1 to 3 antihypertensive drugs to undergo radiofrequency renal denervation (n=38) or a sham control procedure (n=42). All patients remained on antihypertensive drugs. The current analysis of the study showed improved BP control with higher TTR after radiofrequency RDN (33.7% TTR) compared with sham control (18.8% TTR) through three years (P=0.023).

GSR-DEFINE is a prospective, observational study in a real-world patient setting that showed that patients spent 34.9% time in TTR through three years after renal denervation. The study also found that every 10% increase in TTR at 6 months was associated with a 16% decrease in MACE.

Source: Press release Medtronic, May 17, 2022 Also read our summary of the efficacy and safety outcomes at 3 years of SPYRAL HTN-ON MED